Oneview Healthcare Earnings Call Highlights Growth Push

Oneview Healthcare PLC Chess Depository Interests repr 1 ((AU:ONE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Oneview Healthcare PLC’s latest earnings call struck a cautiously upbeat tone as management balanced robust revenue growth and clear strategic progress against persistent losses and funding constraints. Executives highlighted double‑digit top‑line expansion, accelerating deployments and rising AI‑driven productivity, while acknowledging that long sales cycles, pressured margins and modest cash reserves keep execution risk front and center.

Strong Revenue Growth

Revenues rose 21% year on year in 2025, powered by a €1.6 million jump in non‑recurring sales and 7% growth in annual recurring revenue. Management stressed that on a constant currency basis, growth exceeded 25%, underscoring how foreign‑exchange headwinds masked the underlying commercial momentum.

Improved Deployment Momentum

Deployment activity accelerated 31% in the second half of 2025 versus the first, signaling healthier project execution and customer onboarding. This underpins a 2026 target to increase live endpoints by about 20% to just under 18,000, up from 14,880 at year‑end 2025.

Commercial Traction and New Logos

Over the past three years, the company secured 18 new customer logos that collectively manage 11,631 licensed beds, significantly expanding its footprint in key health systems. Management sees a roughly 46,000‑endpoint addressable opportunity across these customers, creating a sizable runway for upsell and expansion.

Strategic Baxter Partnership and GPO Entry

A cornerstone of the call was the deepening partnership with Baxter, which has opened doors to a group purchasing organization tied to one of the top 10 U.S. health systems. The Baxter pipeline now includes more than 156 qualified opportunities, materially broadening Oneview’s access to large, system‑wide deals.

Product and AI Innovation Momentum

On the product side, Oneview introduced a next‑generation front end and the Ovie AI ecosystem, which includes Engage, Voice, Console and Rounds modules. Ovie Console in particular moved from concept to pilot rapidly by leveraging AI, with additional pilots and demonstrations slated at major industry events.

Software Development Productivity Gains

The company has redesigned its software development life cycle around so‑called Agentic AI to boost engineering productivity and shorten delivery timelines. Within two quarters, the share of engineers reporting daily time savings above 15% rose from 58% to 76%, and management is targeting a 4‑out‑of‑5 maturity level across critical SDLC phases in 2026.

Operational Cost Efficiency

Cost discipline featured prominently, with cash operating expenses down 9% in the second half of 2025 compared with the first and 13% lower than the prior‑year period. The second‑half run‑rate implies more than €1.4 million in annualized savings versus the first half, which management plans to carry into 2026.

Gross Margin and Product Mix Transparency

Gross margin for 2025 came in at 64%, a three‑point decline that management attributed to a greater share of lower‑margin non‑recurring revenue rather than channel pressure. Executives reiterated that they expect margins to hold in the mid‑to‑low‑60s range in 2026, even as they continue to push deployment growth.

Board and Leadership Strengthening

Governance and leadership were bolstered with the appointment of Michael Dowling, a long‑time chief executive of a major New York health system, to the board effective December 2025. In parallel, Dr. Greg Jackson was named AI Transformation Lead to drive 54 identified AI initiatives from concept into operational reality.

Ongoing Operating Loss and Cash Position

Despite progress, Oneview remains loss‑making, with operating EBITDA at a negative €8.1 million in 2025, an 8% improvement year on year. Cash on hand at December 31 stood at €4.6 million, and management noted that cash burn was broadly aligned with the EBITDA loss, keeping liquidity a critical focus for investors.

Gross Margin Compression from Revenue Mix

Management revisited gross margin compression, stressing that the three‑point decline to 64% reflects a deliberate revenue mix shift toward more non‑recurring projects. While this weighs on near‑term margin optics, the company argues it is investing in deployments that should expand the installed base and drive higher‑margin recurring revenue over time.

Decommissioning and Customer Budget Pressure

Not all deployment trends were positive, as roughly 900 endpoints were decommissioned at one Australian customer in 2025 amid local budget constraints. However, executives highlighted that new endpoints generate more than twice the revenue per endpoint compared with the decommissioned units, partially offsetting the impact on top‑line growth.

Currency Headwinds

Foreign‑exchange movements weighed on reported numbers, with a weaker Australian dollar and U.S. dollar translation effects muting headline growth. The company emphasized that constant currency growth above 25% better reflects underlying demand, positioning FX as a reporting headwind rather than a fundamental issue.

Sales Cycle Length and Pipeline Conversion Risk

Oneview cautioned that sales cycles in hospital markets remain lengthy at roughly 18 months to two years, which can make revenue timing unpredictable. While the Baxter‑linked pipeline and new GPO access offer significant upside, management acknowledged that conversion and timing are not fully within its control.

Regulatory and Capital Spending Uncertainty

Executives also flagged macro uncertainty in U.S. hospital regulation and capital spending, which could delay some deployment and purchasing decisions. These factors may impact how quickly the company can convert its growing pipeline into live endpoints and recognized revenue, even with strong customer interest.

Dependence on Upsell and Enterprise Expansion

Future growth is expected to lean heavily on upselling new endpoint products and expanding coverage within existing health‑system customers, where the company cited a 92% upsell rate per bed. This strategy highlights a large enterprise conversion opportunity but also raises execution risk if hospitals slow rollouts or tighten budgets.

Forward‑Looking Guidance and Outlook

Looking ahead to 2026, Oneview is guiding to continued revenue momentum with endpoints targeted to grow about 20% to just under 18,000, backed by second‑half deployment acceleration and recent contracts averaging roughly 2.5 endpoints per room. Management expects gross margin to remain in the mid‑to‑low‑60s and plans to extend the more than €1.4 million annualized OpEx savings from late 2025, while leaning on its 18 new logos, Baxter‑driven pipeline and AI‑enabled SDLC efficiency to speed product delivery and deployment.

Oneview’s earnings call painted a picture of a health‑tech player gaining commercial traction and sharpening its operating model, yet still climbing a steep path toward profitability. For investors, the story hinges on whether management can convert its growing pipeline and AI‑enabled productivity gains into sustainable recurring revenue while maintaining discipline on costs and capital in a challenging hospital spending environment.